“In Lena Åredal, we have found the leader we have been looking for for SyntheticMR’s next development phase. Her documented commercial drive and ability to build high-performing teams are important qualities to accelerate the company’s growth. We are facing a phase where, for example, monitoring rare but serious drug side effects will require an increased number of MRI examinations – an area where our technology can make a real difference. The board looks forward to welcoming Lena to the company as soon as possible,” says Gisli Hennermark, Chairman of SyntheticMR.

Lena Åredal

During her time as CEO of Perimed, Lena Åredal has been responsible for the company’s OEM relationships, established a direct sales organization in the US, restructured the global distribution network and led the company’s first external capital raising. Previously, she has held several senior commercial positions within Baxter in the Nordics, where she has built up sales organizations and played a key role in several acquisition and integration processes.

She holds a Master’s degree in Public Health from Karolinska Institutet.